Oncoclínicas do Brasil Serviços Médicos (ONCO3) Q1 2025 earnings summary

Executive summary

• Largest private oncology provider in Brazil, operating 146–149 units with over 2,900 oncology specialists and a 9.1% market share.

• Q1 2025 focused on cash flow preservation, achieving R$131.8M improvement in free cash flow year-over-year.

• Commercial strategy prioritized cash conversion and client diversification, slowing revenue growth but improving working capital.

• Cost and expense reduction initiatives since Q3 2024 yielded over R$32M–34M in normalized savings in Q1 2025.

• Revenue diversification and new partnerships contributed to a healthier revenue mix.

Financial highlights

• Gross revenue in Q1 2025 was R$1,658.1M–1,700M, up 2.3% year-over-year; net revenue reached R$1,493.2M, up 2.4%. LTM gross revenue was R$6.8B (+10% YoY); LTM net revenue was R$6.3B (+10.7% YoY).

• Adjusted EBITDA (Ex-LTIP) in Q1 2025 was R$134.3M (9.0% margin), down from R$240.2M (16.5%) in Q1 2024.

• Net loss in Q1 2025 was R$128M–131.97M, compared to net income of R$19.59M–25.4M in Q1 2024, mainly due to higher costs and non-recurring expenses.

• Operating cash flow was positive at R$10.7M in Q1 2025, with free cash flow improving by R$123M–131.8M year-over-year.

• Net financial result improved to -R$148.2M from -R$191.9M year-over-year.

Outlook and guidance

• Management expects margin and revenue growth to stabilize as the adjustment cycle concludes, with no further significant reductions in average ticket anticipated.

• Price readjustments (CMED) and new partnerships, such as with APIVIDA and Santa Group, are expected to support future growth.

• Saudi Arabia JV targets US$550M gross revenue and US$150M EBITDA by year five; project remains under construction.